Tranilast enhances the anti-tumor effects of tamoxifen on human breast cancer cells in vitro

Journal of Biomedical Science

Ali Ghanbari²  Sara Darakhshan¹ 

[1] Department of biology, Faculty of science, Razi University, Kermanshah, Iran;Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

关键词: Transforming growth factor-beta;    Apoptosis;    Tranilast;    Tamoxifen;    Breast cancer;   

Others  :  823179
DOI  :  10.1186/1423-0127-20-76

 received in 2013-07-07, accepted in 2013-10-14,  发布年份 2013

【 摘 要 】

Background

Tamoxifen is the most widely used anti-estrogen for the treatment of breast cancer. Studies show that the combination therapy with other substances that helps the activity of tamoxifen. The objective of this study was to evaluate the effect of tamoxifen when used in combination with tranilast on human breast cancer cells.

Results

Two MCF-7 and MDA-MB-231 human breast cancer cell lines were treated with tamoxifen and/or tranilast. The cell viability and cytotoxicity was assessed using MTT and LDH assays; the apoptotic effects were examined by TUNEL assay, acridine orange/ethidium bromide staining and DNA laddering, also the expression levels of bax and bcl-2 genes were detected by real-time RT-PCR. The mRNA expression of TGF-β ligands and receptors examined using real-time RT-PCR and TGF-β1 protein secretion levels were also evaluated by ELISA assay. Inhibitory effect of these drugs on invasion and metastasis were tested by wound healing and matrigel invasion assay.

We found that combination of these drugs led to a marked increase in growth and proliferation inhibition compared to either agent alone. Furthermore, bax and bcl-2 affected by tamoxifen and/or tranilast and resulted in a significant increase in bax and decrease in bcl-2 mRNA expression. In addition, treatment with tamoxifen and/or tranilast resulted in significant decreased in TGF-β1, 2, 3, TGF-βRI and II mRNA and TGF-β1 protein levels while TGF-βRIII mRNA level was increased and invasion was also inhibited.

Conclusions

These findings indicate that tranilast, by synergistic effect, enhances the activity of tamoxifen and the TGF-β pathway is a target for this combination therapy, therefore; we propose that this combined treatment may be suitable selection in prevention of breast cancer.

【 授权许可】

   
2013 Darakhshan and Ghanbari; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

【 参考文献 】

• [1]Hengartner MO: The biochemistry of apoptosis. Nature 2000, 407:770-776.
• [2]Johnstone RW, Ruefli AA, Lowe SW: Apoptosis. A Link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
• [3]Mehlen P, Puisieux A: Metastasis: a question of life or death. Nat Rev Cancer 2006, 6:449-458.
• [4]Johansen AM: Breast cancer chemoprevention: a review of selective estrogen receptor modulators. Clin J Oncol Nurs 2005, 9:317-320.
• [5]Higgins MJ, Baselga J: Targeted therapies for breast cancer. Journal of Clinical Invest 2011, 121:3797-3803.
• [6]Roberts CG, Millar EK, O’Toole SA, McNeil CM, Lehrbach GM, Pinese M, et al.: Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene 2011, 30:3186-3197.
• [7]Massague J: TGF-beta signal transduction. Annu Rev Biochem 1998, 67:753-791.
• [8]Hata A, Shi Y, Massague J: TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. Mol Med Today 1998, 4:257-262.
• [9]Fleisch MC, Maxwell CA, Barcellos-Hoff MH: The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr Relat Cancer 2006, 13:379-400.
• [10]Pierce DF Jr, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, et al.: Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev 1993, 7:2308-2317.
• [11]Elliott RL, Blobe GC: Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005, 23:2078-2093.
• [12]Walker RA, Dearing SJ: Transforming growth factor β1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 1992, 28:641-644.
• [13]Azuma H, Banno K, Yoshimura T: Pharmacological properties of N-(3′, 4′-dimethoxycinnamonyl) anthranilic acid, a new antiatopic agent. Br J Pharmacol 1976, 58:483-488.
• [14]Suzawa H, Kikuchi S, Arai N, Koda A: The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol 1992, 60:91-96.
• [15]Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A: Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995, 118:213-221.
• [16]Ikeda H, Inao M, Fujiwara K: Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun 1996, 227:322-327.
• [17]Fukuyama J, Miyazawa K, Hamano S, Ujiie A: Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Can J Physiol Pharmacol 1996, 74:80-84.
• [18]Ochiai H, Ochiai Y, Chihara E: Tranilast inhibits TGF-β1 secretion without affecting its mRNA levels in conjunctival cells. Kobe J Med Sei 2001, 47:203-209.
• [19]Platten M, Wick W, Wischhusen J, Weller M: N-[3, 4- dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). Br J Pharmacol 2011, 134:1279-1284.
• [20]Buck MB, Pfizenmaier K, Knabbe C: Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol 2004, 18:1643-1657.
• [21]Gaverieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119:493-501.
• [22]Zhang T, Chen X, Qu L, Wu J, Cui R, Zhao Y: Chrysin and its phosphate ester inhibit cell proliferation and induce apoptosis in Hela cells. Bioorg Med Chem 2004, 12:6097-6105.
• [23]Savitskiy VP, Shman T, Potapnev MP: Comparative measurament of spontaneous apoptosis in pediatric acute leukemia by different techniques. Cytometry 2003, 56:16-22.
• [24]Renvoize C, Biola A, Pallardy M, Breard J: Apoptosis: identification of dying cell. Cell Biol Toxicol 1998, 14:111-120.
• [25]Ayusawa D, Arai H, Wataya Y, Seno T: A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse sel FM3A. Mutat Res 1988, 200:221-230.
• [26]Canman CE, Tang HY, Normolle DP, Lawrence TS, Maybaum J: Variation in patients of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: Implications for mechanism of recistance and cytotoxicity. Proc Natl Acad Sci USA 1992, 89:10474-10478.
• [27]Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR, Sikorska M: Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993, 12:3679-3684.
• [28]Reed J, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime- Sempe C, Bodrug S, Kitada S, Hanada M: Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to theraphy. J Cell Biochem 1996, 60:23-32.
• [29]Adam JM, Cory S: The bcl-2 protein family: Arbiters of cell survival. Science 1998, 281:1322-1326.
• [30]Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574.
• [31]Renoir JM, Bouclier C, Seguin A, Marsaud V, Sola B: Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells. J Mol Endocrinol 2008, 40:101-112.
• [32]Thiantanawat A, Long BJ, Brodie AM: Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003, 63:8037-8050.
• [33]Maccarrone M, Fantini C, Ranalli M, Melino G, Agro AF: Activation of nitric oxide synthase is involved in tamoxifen-induced apoptosis of human erythroleukemia K562 cells. FEBS Lett 1998, 434:421-424.
• [34]Stewart BW: Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. Journal of National Cancer Institute 1994, 86:1286-1296.
• [35]Adams JM, Cory S: Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007, 19:488-496.
• [36]Metcalfe AD, Gilmore A, Klinowska T, Oliver J, Valentijn AJ, Brown R, Ross A, MacGregor G, Hickman JA, Streuli CH: Developmental regulation of bcl-2 family protein expression in the involuting mammary gland. J Cell Sci 1999, 112:1771-1783.
• [37]Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, Tsuchiya A, Abe R, Takenoshita S: Tamoxifen-induced apoptosis in breast cancer cells related to down regulation of bcl-2, but not bax and bcl-XL, without alteration of p53 protein levels. Clin Cancer Res 1999, 5:2971-2977.
• [38]Salami S, Karami-Tehrani F: Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem 2003, 36:247-253.
• [39]Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, et al.: Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther 2008, 7:800-808.
• [40]Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB: The growth inhibition of human breast cancer cells by a novel syntheticbprogestin involves the induction of transforming growth factor beta. J Clin Invest 1991, 87:277-283.
• [41]Mulder KM: Role of Ras and Mapks in TGF beta signaling. Cytokine Growth Factor Rev 2000, 11:23-35.
• [42]Basolo F, Fiore L, Ciardiello F, Calvo S, Fontanini G, Conaldi PG, Toniolo A: Response of normal and oncogenetransformed human mammary epithelial cells to transforming growth factor beta 1 (TGF-beta 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. Int J Cancer 1994, 56:736-742.
• [43]Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA: Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Cancer Res 1992, 52:6949-6952.
• [44]McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, et al.: Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 2001, 91:76-82.
• [45]Bierie B, Moses HL: Tumour microenvironment: TGF beta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520.
• [46]Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U.S.A. 2003, 100:8621-8623.
• [47]Lei XF, Bandyopadhyay A, Le T, Sun LZ: Autocrine TGF beta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 2002, 21:7514-7523.
• [48]Arrick BA, Korc M, Derynck R: Differential regulation of expression of three transforming growth factor/3 species in human breast cancer cell lines by estradiol. Cancer Res 1990, 50:299-303.
• [49]Shi XP, Miao S, Wu Y, Zhang W, Zhang XF, Ma HZ, Xin HL, Feng J, Wen AD, Li Y: Resveratrol Sensitizes Tamoxifen in Antiestrogen-Resistant Breast Cancer Cells with Epithelial Mesenchymal Transition Features. Int J Mol Sci 2013, 14:15655-15668.
• [50]Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC: The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 2007, 117:206-217.
• [51]Yingling JM, Blanchard KL, Sawyer JS: Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004, 3:1011-1022.
• [52]Rajput S, Kumar BN, Sarkar S, Das S, Azab B, Santhekadur PK, Das SK, Emdad L, Sarkar D, Fisher PB, Mandal M: Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer. Plos One 2013, 8:e61342.
• [53]Kumar BN, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, Mandal M: Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 2013, 13:273. BioMed Central Full Text
• [54]Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, et al.: ZD6474 Enhances Paclitaxel Antiproliferative and Apoptotic Effects in Breast Carcinoma Cells. J Cell Physiol 2011, 226:375-384.
• [55]Aberg UW, Saarinen N, Abrahamsson A, Nurmi T, Engblom S, et al.: Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo. PLoS One 2011, 6:e25720.
• [56]Subramaniam V, Chakrabarti R, Prud’homme GJ, Jothy S: Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs 2010, 21:351-361.
• [57]Shime H, Kariya M, Orii A, Momma C, Kanamori T, Fukuhara K, et al.: Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21waf1 and p53. J Clin Endocrinol Metab 2002, 87:5610-5617.
• [58]Sato S, Takahashi S, Asamoto M, Naiki T, Naiki-Ito A, Asai K, Shirai T: Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro. Prostate 2010, 70:229-238.
• [59]Yamamoto M, Yamauchi T, Okano K, Takahashi M, Watabe S, Yamamoto Y: Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Tohoku J Exp Med 2009, 217:193-201.
• [60]Prud’homme GJ: Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007, 87:1077-1091.